Discovery of Sunitinib as a Multitarget Treatment of Cancer

S. E. DePrimo, A. Cheng, S. Lanzalone, M. J. Lechuga, C. S. Harmon, X. Lin, E. Raymond, S. J. Faivre, Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters Journal of Clinical Oncology. ,vol. 26, pp. 4593- 4593 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4593

Zhong-Lin Zhang, Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World Journal of Gastroenterology. ,vol. 12, pp. 4241- 4245 ,(2006) , 10.3748/WJG.V12.I26.4241

Timothy J. Hemesath, E. Roydon Price, Clifford Takemoto, Tina Badalian, David E. Fisher, MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes Nature. ,vol. 391, pp. 298- 301 ,(1998) , 10.1038/34681

Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381

J.L. Raoul, P. Niccoli, Y.J. Bang, I. Borbath, C. Lombard-Bohas, P. Metrakos, A. Vinik, D.R. Lu, C. Blanckmeister, E. Raymond, 6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial Ejc Supplements. ,vol. 7, pp. 361- 361 ,(2009) , 10.1016/S1359-6349(09)71223-6

Gavin M Marx, Christopher B Steer, Peter Harper, Nick Pavlakis, Olivier Rixe, David Khayat, None, Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock! Journal of Clinical Oncology. ,vol. 20, pp. 1446- 1448 ,(2002) , 10.1200/JCO.2002.20.6.1446

Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857

Lesley J. Murray, Tinya J. Abrams, Kelly R. Long, Theresa J. Ngai, Lisa M. Olson, Weiru Hong, Paul K. Keast, Jacqueline A. Brassard, Anne Marie O'Farrell, Julie M. Cherrington, Nancy K. Pryer, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical & Experimental Metastasis. ,vol. 20, pp. 757- 766 ,(2003) , 10.1023/B:CLIN.0000006873.65590.68

S. George, J.Y. Blay, P.G. Casali, A. Le Cesne, P. Stephenson, S.E. DePrimo, C.S. Harmon, C.N.J. Law, J.A. Morgan, I. Ray-Coquard, V. Tassell, D.P. Cohen, G.D. Demetri, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. European Journal of Cancer. ,vol. 45, pp. 1959- 1968 ,(2009) , 10.1016/J.EJCA.2009.02.011

Katherine L. Osusky, Dennis E. Hallahan, Allie Fu, Fei Ye, Yu Shyr, Ling Geng, The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis. ,vol. 7, pp. 225- 233 ,(2004) , 10.1007/S10456-004-3149-Y